PER 0.00% 8.0¢ percheron therapeutics limited

Prof Thomas Voit, DMD expert, interview with Wilsons advisory, page-19

  1. 236 Posts.
    lightbulb Created with Sketch. 59
    Great points everyone couldn't agree more with all that's been said, touching on Bellas post regarding, Could ATL 1102 be used for ambulatory patients? "Absolutely! Use this as early as possible - before the boys are aged 4 years...it will be definitely beneficial'' I noted that he briefly mentioned they had discussed plans for trials in ambulant population. I really hope this is something they don't sit on and get the machine rolling so to speak about getting a trial happening very quickly post or even pre Phase2b trial ending. I'm usure if they would have to start at phase 1 or skip to phase 2a due to current safety profile, maybe someone can enlighten me.

    Plus Its nice for this thread to mostly be positive and not becoming and ego slanging match that it usually succumbs to.
 
watchlist Created with Sketch. Add PER (ASX) to my watchlist
(20min delay)
Last
8.0¢
Change
0.000(0.00%)
Mkt cap ! $72.12M
Open High Low Value Volume
7.9¢ 8.0¢ 7.9¢ $12.63K 158.7K

Buyers (Bids)

No. Vol. Price($)
2 66500 7.6¢
 

Sellers (Offers)

Price($) Vol. No.
8.0¢ 273231 2
View Market Depth
Last trade - 15.26pm 19/07/2024 (20 minute delay) ?
PER (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.